Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Olaparib (Lynparza) for Ovarian Cancer (Resubmission)
(Final Recommendation Issued as of September 20, 2017)

Ribociclib (Brand Name: TBD) for Advanced or Metastatic Breast Cancer
(Pending Submission as of September 18, 2017)

Nivolumab (Opdivo) for Squamous Cell Carcinoma of the Head & Neck
(Notification to Implement Issued as of September 18, 2017)

Rituximab (Rituxan) for Acute Lymphoblastic Leukemia
(Notification to Implement Issued as of September 18, 2017)

Blinatumomab (Blincyto) for Adult Acute Lymphoblastic Leukemia (Resubmission)
(Notification to Implement Issued as of September 18, 2017)

Regorafenib (Stivarga) for Unresectable Hepatocellular Carcinoma
(Pending Submission as of September 13, 2017)

Avelumab (Brand Name: TBD) for metastatic Merkel Cell Carcinoma
(Pending Submission as of September 11, 2017)

Panitumumab (Vectibix) for Left Sided Metastatic Colorectal Cancer
(Open for Input on Submission until September 22, 2017)

Cabozantinib (Brand Name: TBD) for Advanced Renal Cell Carcinoma 
(Pending Submission as of September 1, 2017)

Nivolumab (Opdivo) for classical Hodgkin Lymphoma 
(Pending Submission as of August 30, 2017)

Olaratumab (Brand Name: TBD) for Advanced Soft Tissue Sarcoma
(Pending Submission as of August 22, 2017)

 

Find a Drug Review